Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
This is an extension study trial. Eligible participants from the RPC01-3101 and RPC01-202 trials were able to roll-over in this trial to receive study medication until March 2023 or until the Sponsor discontinues the development program, whichever comes first.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com
Previously participated in a trial of RPC1063 and meets the criteria for participation in the open-label extension as outlined in the prior trial
You may not be if
Receiving treatment with breast cancer resistance protein inhibitors
Clinically relevant cardiovascular conditions
Liver function impairment
Clareo Health | An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
